Everolimus with reduced calcineurin inhibitor in thoracic transplant recipients with renal dysfunction: a multicenter, randomized trial.

@article{Gullestad2010EverolimusWR,
  title={Everolimus with reduced calcineurin inhibitor in thoracic transplant recipients with renal dysfunction: a multicenter, randomized trial.},
  author={Lars Gullestad and Martin Iversen and Svend-Aage Mortensen and Hans E Eiskjaer and Gerdt C. Riise and Lena Mared and Oystein Bj\ortuft and Bj{\"o}rn Ekmehag and K. Jansson and Svein Simonsen and Einar Gude and Bengt Rundqvist and Hans Eirik Fagertun and Dag O Solbu and C M Bergh},
  journal={Transplantation},
  year={2010},
  volume={89 7},
  pages={864-72}
}
BACKGROUND The proliferation signal inhibitor everolimus offers the potential to reduce calcineurin inhibitor (CNI) exposure and alleviate CNI-related nephrotoxicity. Randomized trials in maintenance thoracic transplant patients are lacking. METHODS In a 12-month, open-labeled, multicenter study, maintenance thoracic transplant patients (glomerular filtration rate > or =20 mL/min/1.73m and <90 mL/min/1.73 m) >1 year posttransplant were randomized to continue their current CNI-based… CONTINUE READING